Gilead Sciences Past Earnings Performance
Past criteria checks 5/6
Gilead Sciences has been growing earnings at an average annual rate of 8.3%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 5.5% per year. Gilead Sciences's return on equity is 25.8%, and it has net margins of 20%.
Key information
8.3%
Earnings growth rate
9.1%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 5.5% |
| Return on equity | 25.8% |
| Net Margin | 20.0% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gilead Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 27,382 | 5,484 | 6,401 | 5,557 |
| 31 Mar 23 | 27,043 | 5,583 | 5,909 | 5,259 |
| 31 Dec 22 | 27,281 | 4,592 | 5,673 | 4,977 |
| 30 Sep 22 | 27,136 | 3,334 | 5,303 | 4,746 |
| 30 Jun 22 | 27,515 | 4,137 | 5,280 | 4,727 |
| 31 Mar 22 | 27,472 | 4,515 | 5,274 | 4,714 |
| 31 Dec 21 | 27,305 | 6,225 | 5,246 | 4,601 |
| 30 Sep 21 | 27,482 | 7,394 | 5,083 | 4,655 |
| 30 Jun 21 | 26,638 | 5,162 | 4,999 | 4,713 |
| 31 Mar 21 | 25,564 | 301 | 4,887 | 4,924 |
| 31 Dec 20 | 24,689 | 123 | 5,112 | 4,927 |
| 30 Sep 20 | 23,147 | 1,268 | 4,625 | 4,560 |
| 30 Jun 20 | 22,174 | -257 | 4,571 | 4,432 |
| 31 Mar 20 | 22,716 | 4,962 | 4,427 | 4,002 |
| 31 Dec 19 | 22,449 | 5,386 | 4,381 | 4,055 |
| 30 Sep 19 | 22,365 | 2,693 | 4,308 | 4,086 |
| 30 Jun 19 | 22,357 | 5,955 | 4,204 | 3,995 |
| 31 Mar 19 | 22,320 | 5,892 | 4,089 | 4,318 |
| 31 Dec 18 | 22,127 | 5,455 | 4,056 | 3,920 |
| 30 Sep 18 | 22,281 | 1,587 | 4,177 | 4,218 |
| 30 Jun 18 | 23,197 | 2,208 | 4,108 | 4,068 |
| 31 Mar 18 | 24,690 | 3,464 | 4,025 | 3,740 |
| 31 Dec 17 | 26,107 | 4,628 | 3,878 | 3,734 |
| 30 Sep 17 | 27,478 | 11,601 | 3,618 | 3,591 |
| 30 Jun 17 | 28,466 | 12,213 | 3,570 | 3,826 |
| 31 Mar 17 | 29,101 | 12,637 | 3,563 | 4,446 |
| 31 Dec 16 | 30,390 | 13,501 | 3,398 | 4,666 |
| 30 Sep 16 | 31,576 | 15,076 | 3,472 | 4,416 |
| 30 Jun 16 | 32,371 | 16,346 | 3,544 | 4,135 |
| 31 Mar 16 | 32,839 | 17,341 | 3,466 | 3,469 |
| 31 Dec 15 | 32,639 | 18,108 | 3,426 | 3,014 |
| 30 Sep 15 | 31,447 | 16,912 | 3,236 | 2,952 |
| 30 Jun 15 | 29,194 | 15,043 | 3,278 | 2,839 |
| 31 Mar 15 | 27,485 | 14,207 | 3,080 | 2,608 |
| 31 Dec 14 | 24,890 | 12,101 | 2,983 | 2,854 |
| 30 Sep 14 | 20,696 | 9,406 | 2,561 | 2,409 |
| 30 Jun 14 | 17,437 | 7,463 | 2,023 | 2,295 |
| 31 Mar 14 | 13,669 | 4,580 | 1,814 | 2,220 |
| 31 Dec 13 | 11,202 | 3,075 | 1,699 | 2,120 |
| 30 Sep 13 | 10,585 | 3,046 | 1,538 | 1,952 |
| 30 Jun 13 | 10,229 | 2,933 | 1,451 | 1,902 |
| 31 Mar 13 | 9,867 | 2,872 | 1,379 | 1,785 |
| 31 Dec 12 | 9,702 | 2,592 | 1,280 | 1,652 |
| 30 Sep 12 | 9,315 | 2,494 | 1,315 | 1,622 |
Quality Earnings: 000935700 has high quality earnings.
Growing Profit Margin: 000935700's current net profit margins (20%) are higher than last year (15%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000935700's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: 000935700's earnings growth over the past year (32.6%) exceeds its 5-year average (8.3% per year).
Earnings vs Industry: 000935700 earnings growth over the past year (32.6%) exceeded the Biotechs industry -26.8%.
Return on Equity
High ROE: Whilst 000935700's Return on Equity (25.8%) is high, this metric is skewed due to their high level of debt.